Methotrexate in psoriasis and psoriatic arthritis

Laura C. Coates, Joseph F. Merola, Suzanne M. Grieb, Philip J. Mease, Kristina Callis Duffin

Research output: Contribution to journalArticlepeer-review

Abstract

Methotrexate (MTX) is the most commonly prescribed first-line therapy in psoriatic arthritis (PsA) internationally and is also commonly used in the treatment of psoriasis. However, data supporting its use in PsA are limited and significant toxicities can occur. This article summarizes a debate at the 2019 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting that focused on the use of MTX in psoriasis and PsA. Four clinicians and 1 patient research partner presented clinical study data and the patient experience summarizing the efficacy, tolerability, and toxicity of MTX for both skin and musculoskeletal manifestations. A survey of attending GRAPPA members collected data on current and planned future use of MTX across the world.

Original languageEnglish (US)
Pages (from-to)31-35
Number of pages5
JournalJournal of Rheumatology
Volume96
DOIs
StatePublished - Jun 1 2020

Keywords

  • Grappa
  • Methotrexate
  • Patient research partners
  • Psoriasis
  • Psoriatic arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Methotrexate in psoriasis and psoriatic arthritis'. Together they form a unique fingerprint.

Cite this